US stock · Healthcare sector · Biotechnology
Company Logo

Alnylam Pharmaceuticals, Inc.

ALNYNASDAQ

200.78

USD
-1.93
(-0.95%)
Market Closed
-24.75P/E
-46Forward P/E
-1.24P/E to S&P500
24.099BMarket CAP
- -Div Yield
Upcoming Earnings
26 Oct-31 Oct
Shares Short
8/31/22
4.2M
Short % of Float
4.13%
Short % of Shares Outs.
3.50%
% Held by Insiders
0.54%
% Held by Institutions
100.95%
Beta
0.57
PEG Ratio
0.16
52w. high/low
236.80/117.58
Avg. Daily Volume
1.03M
Return %
Stock
S&P 500
1 year
7.23
(16.94)
3 years
143.99
24.12
5 years
75.72
47.77
Scale: |
High
Low
37.35
14.87
36.37
16.37
26.36
14.82
19.29
8.79
12.34
5.88
21.38
8.33
67.97
18.61
112.57
47.03
140.00
71.14
98.00
31.38
147.63
35.98
153.99
60.27
125.72
65.81
167.33
84.97
212.00
124.00
236.80
117.58
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
0.84
1.32
2.34
2.41
2.38
1.95
1.33
0.77
0.68
0.49
0.55
0.99
0.74
2.01
4.29
7.34
7.38
Earnings per share
(1.09)
(2.21)
(0.64)
(1.14)
(1.04)
(1.36)
(2.11)
(1.45)
(4.85)
(3.45)
(4.79)
(5.42)
(7.57)
(8.11)
(7.46)
(7.42)
(8.18)
FCF per share
(0.93)
4.88
1.33
(1.85)
(2.12)
(2.08)
(2.47)
(1.18)
(2.35)
(2.41)
(4.35)
(5.38)
(6.85)
(3.83)
(5.96)
(5.46)
(4.42)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.16
0.20
0.26
0.12
0.11
0.03
0.17
0.07
0.12
0.15
0.75
1.15
1.26
1.28
0.61
(0.12)
(0.40)
Book Value per sh.
6.31
5.15
4.92
4.27
3.76
2.78
2.67
4.39
12.60
15.06
10.75
19.51
12.94
13.17
8.84
5.12
4.01
Comm.Shares outs.
32
39
41
42
42
42
50
62
74
84
86
91
101
109
115
115
120
Avg. annual P/E ratio
(14.6)
(10.7)
(42.4)
(17.7)
(14.5)
(6.6)
(6.8)
(27.5)
(15.3)
(30.5)
(12.9)
(14.9)
(13.6)
(10.5)
(17.6)
(22.3)
(24.8)
P/E to S&P500
(0.8)
(0.6)
(2.0)
(0.2)
(0.7)
(0.4)
(0.5)
(1.6)
(0.8)
(1.5)
(0.6)
(0.6)
(0.5)
(0.4)
(0.5)
(0.7)
(1.2)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
27
51
96
101
100
83
67
47
51
41
47
90
75
220
493
844
884
Operating margin
(146.7)%
(183.1)%
(28.9)%
(47.9)%
(44.1)%
(66.2)%
(194.0)%
(197.0)%
(801.0)%
(720.3)%
(900.3)%
(556.2)%
(1,087.6)%
(427.5)%
(168.1)%
(83.9)%
(81.5)%
Depreciation (m)
4
4
6
6
5
5
9
10
12
19
15
13
6
54
35
48
63
Net profit (m)
(35)
(85)
(26)
(48)
(44)
(58)
(106)
(89)
(360)
(290)
(410)
(491)
(761)
(886)
(858)
(853)
(981)
Income tax rate
- -
(6.5)%
(2.8)%
(1.2)%
(1.2)%
- -
9.1%
2.9%
10.0%
- -
- -
- -
(0.1)%
(0.1)%
(0.3)%
0.1%
(0.1)%
Net profit margin
(128.5)%
(167.9)%
(27.3)%
(47.3)%
(43.5)%
(69.7)%
(158.9)%
(189.2)%
(712.8)%
(705.8)%
(869.6)%
(545.9)%
(1,016.6)%
(403.2)%
(174.1)%
(101.0)%
(111.3)%
Working capital (m)
200
381
343
183
152
71
77
200
651
1,043
540
1,620
1,021
1,363
1,530
2,113
1,814
Long-term debt (m)
6
3
- -
- -
- -
- -
- -
- -
- -
- -
150
30
30
- -
484
957
950
Equity (m)
201
199
202
178
158
118
134
270
936
1,265
920
1,766
1,302
1,439
1,016
588
176
ROIC
- -
(20.8)%
(5.6)%
(12.8)%
(14.9)%
(28.7)%
(44.3)%
(24.3)%
(36.6)%
(21.9)%
(36.3)%
(26.5)%
(54.6)%
(43.4)%
(27.4)%
(33.8)%
(41.3)%
Return on capital
(14.4)%
(16.2)%
(4.4)%
(9.8)%
(10.9)%
(20.4)%
(40.5)%
(21.9)%
(37.1)%
(20.9)%
(32.5)%
(24.6)%
(48.3)%
(37.0)%
(22.6)%
(27.4)%
(33.1)%
Return on equity
(17.2)%
(42.9)%
(13.0)%
(26.7)%
(27.5)%
(48.9)%
(79.1)%
(33.0)%
(38.5)%
(22.9)%
(44.6)%
(27.8)%
(58.5)%
(61.6)%
(84.5)%
(145.0)%
(557.1)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
28 Jul · 2022 | Q2
All numbers in millions
Total liabilities
$ 3,154
Total assets
$ 3,330
Long-term debt
$ 950
Cash and equiv.
$ 576
Goodwill
$ - -
Retained earnings
$ (5,956)
Common stock
121
Enterprise Value
$ 24,473
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,536
1,874
2,369
Receivables
43
102
199
Inventory
56
75
86
Other
80
12
428
Current assets
1,716
2,115
2,809
Acc. Payable
50
52
73
Debt due
28
37
322
Other
275
496
300
Current liabilities
353
585
696
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
71.31%
93.06%
48.54%
Cash flow
(8.35)%
14.42%
31.93%
Earnings
(0.64)%
16.93%
44.15%
Dividends
- -
- -
- -
Book value
(42.12)%
(21.82)%
40.06%
Insider Trading
Type
Shares
Date
Sigal Charles Elliott
Award
4,456
08/22/22
Sharp Phillip A
Exempt
30,000
08/15/22
Sharp Phillip A
Exempt
30,000
08/15/22
Sharp Phillip A
Sale
715
08/15/22
Sharp Phillip A
Sale
3,853
08/15/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
99
104
126
164
493
2021
178
221
188
259
844
2022
213
225
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(1.58)
(1.56)
(2.20)
(2.12)
(7.46)
2021
(1.74)
(1.65)
(1.78)
(2.25)
(7.42)
2022
(2.01)
(2.29)
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. John Maraganore
Full-time employees:
1,665
City:
Cambridge
Address:
675 W Kendall St
IPO:
May 28, 2004
Website:
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Recent News